The EIC-Transition proposal — iCURE “Novel small molecule FPR1 agonists for treating antibiotic-resistant and chronic bacterial infections” coordinated

Invited as presenter at the Immunotherapies & Innovations for Infectious Diseases Congress (#I4ID2025) – in Lyon, CEO of

Chairman Dr Sara Malcus and CEO Peter Olofsson-Sahl participated in the Nordic Life Science days. Reconnecting with several

Inicures founders and researchers Professor Johan Bylund at the University of Gothenburg, together with Dr. Peter Olofsson-Sahl at

CEO, Peter Olofsson-Sahl presented Inicure at the #BiotechHanse event as innovative Swedish Life Science innovation for Sweden-Germany collaboration

As partner to the IMPACT project led by University Southern Denmark (SDU) and professor Thomas Andersen, Inucure is

Inicure have been granted support from VINNOVA Planeringsbidrag to improve our EIC Transition proposal. Inicure is coordinating a

Presenting Inicure at the pitching final at the European AMR conference in Basel 25-26 February 2025 (at minute

Looking forward to meet research partners and investors at the GoWest – Nordic capital forum 29-30 January.

More about the publication

The critical role and immunological mechanism of activation of FPR and the significance of NADPH oxidase 2 (NOX2)-derived

We are now live.